{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.","groups":[{"description":"Evaluable Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at DL1 (HR: 3.5 mg/kg/day; SR: 4 mg/kg/day)","id":"OG000","title":"Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 1)"},{"description":"Evaluable Arm C, IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)","id":"OG001","title":"Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 2)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Arm C patients of Safety Phase who were evaluable for DLT. The first 10 evaluable patients enrolled on each dose level were included for monitoring dose limiting toxicity.","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks from start of induction","title":"Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)","type":"SECONDARY","unitOfMeasure":"Participants"}